Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $24.8 million.

  • Intellia Therapeutics' Current Deferred Revenue fell 4462.71% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year decrease of 4462.71%. This contributed to the annual value of $38.9 million for FY2024, which is 3619.43% down from last year.
  • Intellia Therapeutics' Current Deferred Revenue amounted to $24.8 million in Q3 2025, which was down 4462.71% from $29.7 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Current Deferred Revenue registered a high of $127.2 million during Q4 2021, and its lowest value of $24.8 million during Q3 2025.
  • In the last 5 years, Intellia Therapeutics' Current Deferred Revenue had a median value of $55.6 million in 2024 and averaged $62.2 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Current Deferred Revenue skyrocketed by 16646.79% in 2021, and later tumbled by 6761.83% in 2023.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Current Deferred Revenue stood at $127.2 million in 2021, then plummeted by 49.88% to $63.8 million in 2022, then fell by 4.36% to $61.0 million in 2023, then plummeted by 36.19% to $38.9 million in 2024, then crashed by 36.31% to $24.8 million in 2025.
  • Its Current Deferred Revenue stands at $24.8 million for Q3 2025, versus $29.7 million for Q2 2025 and $33.8 million for Q1 2025.